Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Su-Yi Kang"'
Despite advances in cellular network technology, base station (BS) load balancing remains a persistent problem. Although centralized resource allocation methods can address the load balancing problem, it still remains an NP-hard problem. In this rese
Externí odkaz:
http://arxiv.org/abs/2403.08813
Autor:
Qin Wang, Yan Qin, Su-Yi Kang, Xiao-Hui He, Peng Liu, Sheng Yang, Sheng-Yu Zhou, Chang-Gong Zhang, Lin Gui, Jian-Liang Yang, Yan Sun, Yuan-Kai Shi
Publikováno v:
Chinese Medical Journal, Vol 129, Iss 23, Pp 2780-2785 (2016)
Background: The International Prognostic Score (IPS) was developed based on the data of Western advanced Hodgkin lymphoma (HL) patients treated before 1992. Only a few studies ever evaluated the application value of IPS in Chinese population or in pa
Externí odkaz:
https://doaj.org/article/4b3954bbaaea4000bb7046d8e82a85bb
Autor:
Chang Gong Zhang, Yuan Kai Shi, Sheng Yang, Qin Wang, Sheng Yu Zhou, Yan Sun, Yan Qin, Jian Liang Yang, Su Yi Kang, Peng Liu, X H He, Lin Gui
Publikováno v:
Chinese Medical Journal, Vol 129, Iss 23, Pp 2780-2785 (2016)
Chinese Medical Journal
Chinese Medical Journal
Background: The International Prognostic Score (IPS) was developed based on the data of Western advanced Hodgkin lymphoma (HL) patients treated before 1992. Only a few studies ever evaluated the application value of IPS in Chinese population or in pa
Publikováno v:
Journal of Huazhong University of Science and Technology [Medical Sciences]. 34:260-264
This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with the dose-dense ABVD regimen (ABVD-21) in terms of efficacy and toxicity. Patients who had early-stage unfavorable or advanced Ho
Autor:
Lin Yang, Tao Qu, Yan Song, Shu-zhen Shi, Aiping Zhou, Zhaoxu Zheng, Su-yi Kang, Yihebali Chi, Jinwan Wang, Wen-chang Jiang, Yongkun Sun
Publikováno v:
Journal of Clinical Oncology. 29:e21021-e21021
e14668 Background: Nimotuzumab, a humanized IgG1 anti-EGFR monoclonal antibody, has demonstrated efficacy associated with an absence of severe skin toxicity in many phase I/II cancer trials. Methods: This is a single-center, parallel assignment and o
Publikováno v:
Applied Mechanics and Materials; August 2013, Vol. 351 Issue: 1 p1047-1051, 5p